BridgeBio Pharma BBIO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's total current liabilities?
- BridgeBio Pharma (BBIO) reported total current liabilities of $816.37M in Q1 2026.
- How has BridgeBio Pharma's total current liabilities changed year-over-year?
- BridgeBio Pharma's total current liabilities increased by 436.7% year-over-year, from $152.11M to $816.37M.
- What is the long-term trend for BridgeBio Pharma's total current liabilities?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total current liabilities has grown at a 24.7% compound annual growth rate (CAGR), from $95.65M to $287.97M.
- What does total current liabilities mean?
- The total amount of debt and other obligations due within the next twelve months.
- How do you interpret total current liabilities?
- A lower ratio relative to current assets indicates a stronger liquidity position and lower risk of insolvency.
- How does total current liabilities compare across companies?
- Biotech companies typically aim to keep current liabilities well-covered by cash and cash equivalents to ensure operational continuity.